Literature DB >> 18423407

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

James A McCubrey1, Melissa L Sokolosky, Brian D Lehmann, Jackson R Taylor, Patrick M Navolanic, William H Chappell, Stephen L Abrams, Kristin M Stadelman, Ellis W T Wong, Negin Misaghian, Stefan Horn, Jörg Bäsecke, Massimo Libra, Franca Stivala, Giovanni Ligresti, Agostino Tafuri, Michele Milella, Marek Zarzycki, Andrzej Dzugaj, Francesca Chiarini, Camilla Evangelisti, Alberto M Martelli, David M Terrian, Richard A Franklin, Linda S Steelman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18423407      PMCID： PMC2583357          DOI： 10.1016/j.advenzreg.2008.02.006

Source DB:  PubMed          Journal:  Adv Enzyme Regul        ISSN： 0065-2571


× No keyword cloud information.
  199 in total

1.  Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1).

Authors:  P F Dijkers; R H Medema; C Pals; L Banerji; N S Thomas; E W Lam; B M Burgering; J A Raaijmakers; J W Lammers; L Koenderman; P J Coffer
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma.

Authors:  M Arcinas; C A Heckman; J W Mehew; L M Boxer
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

3.  Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase.

Authors:  J Xing; D D Ginty; M E Greenberg
Journal:  Science       Date:  1996-08-16       Impact factor: 47.728

4.  Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue.

Authors:  E Leygue; H Dotzlaw; P H Watson; L C Murphy
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

5.  Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function.

Authors:  Xiao-Jun Qi; Gary M Wildey; Philip H Howe
Journal:  J Biol Chem       Date:  2005-11-10       Impact factor: 5.157

6.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.

Authors:  L D Mayo; D B Donner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

Review 7.  Ras signaling in prostate cancer progression.

Authors:  Michael J Weber; Daniel Gioeli
Journal:  J Cell Biochem       Date:  2004-01-01       Impact factor: 4.429

8.  Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.

Authors:  W L Blalock; P M Navolanic; L S Steelman; J G Shelton; P W Moye; J T Lee; R A Franklin; A Mirza; M McMahon; M K White; J A McCubrey
Journal:  Leukemia       Date:  2003-06       Impact factor: 11.528

Review 9.  Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.

Authors:  Amit Panwalkar; Srdan Verstovsek; Francis J Giles
Journal:  Cancer       Date:  2004-02-15       Impact factor: 6.860

Review 10.  Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.

Authors:  A M Martelli; P L Tazzari; C Evangelisti; F Chiarini; W L Blalock; A M Billi; L Manzoli; J A McCubrey; L Cocco
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530
View more
  9 in total

1.  Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.

Authors:  Martin Bezler; Jan G Hengstler; Axel Ullrich
Journal:  Mol Oncol       Date:  2012-07-20       Impact factor: 6.603

Review 2.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

3.  Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model.

Authors:  Jennifer Perez; Anne Valérie Decouvelaere; Thomas Pointecouteau; Daniel Pissaloux; Jean Philippe Michot; Anthony Besse; Jean Yves Blay; Aurélie Dutour
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

4.  Deguelin induces the apoptosis of lung cancer cells through regulating a ROS driven Akt pathway.

Authors:  Huae Xu; Xiaolin Li; Wenqiu Ding; Xiaoning Zeng; Hui Kong; Hong Wang; Weiping Xie
Journal:  Cancer Cell Int       Date:  2015-02-25       Impact factor: 5.722

5.  Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.

Authors:  Maren Bredemeier; Sabine Kasimir-Bauer; Hans-Christian Kolberg; Thomas Herold; Sarah Synoracki; Siegfried Hauch; Philippos Edimiris; Agnes Bankfalvi; Mitra Tewes; Rainer Kimmig; Bahriye Aktas
Journal:  Mol Med Rep       Date:  2017-03-30       Impact factor: 2.952

6.  The effect of tetrandrine combined with cisplatin on proliferation and apoptosis of A549/DDP cells and A549 cells.

Authors:  Ling-Yun Ye; Song Hu; Hua-E Xu; Rong-Rong Xu; Hui Kong; Xiao-Ning Zeng; Wei-Ping Xie; Hong Wang
Journal:  Cancer Cell Int       Date:  2017-03-27       Impact factor: 5.722

7.  Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.

Authors:  Paul Ellis; Peter Barrett-Lee; Lindsay Johnson; David Cameron; Andrew Wardley; Susan O'Reilly; Mark Verrill; Ian Smith; John Yarnold; Robert Coleman; Helena Earl; Peter Canney; Chris Twelves; Christopher Poole; David Bloomfield; Penelope Hopwood; Stephen Johnston; Mitchell Dowsett; John M S Bartlett; Ian Ellis; Clare Peckitt; Emma Hall; Judith M Bliss
Journal:  Lancet       Date:  2009-05-16       Impact factor: 79.321

8.  Musashi-1 regulates AKT-derived IL-6 autocrinal/paracrinal malignancy and chemoresistance in glioblastoma.

Authors:  Hsiao-Yun Chen; Liang-Ting Lin; Mong-Lien Wang; Shu-Hsien Lee; Ming-Long Tsai; Chi-Chang Tsai; Wei-Hsiu Liu; Tzu-Chien Chen; Yi-Ping Yang; Yi-Yen Lee; Yuh-Lih Chang; Pin-I Huang; Yi-Wei Chen; Wen-Liang Lo; Shih-Hwa Chiou; Ming-Teh Chen
Journal:  Oncotarget       Date:  2016-07-05

9.  Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.

Authors:  Stephen L Abrams; Peter P Ruvolo; Vivian R Ruvolo; Giovanni Ligresti; Alberto M Martelli; Lucio Cocco; Stefano Ratti; Agostino Tafuri; Linda S Steelman; Saverio Candido; Massimo Libra; James A McCubrey
Journal:  Oncotarget       Date:  2017-08-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.